



*In Hypertensive Emergencies*

# **You Have No Time to Waste**

## **Update to Ready-to-Use CARDENE I.V.**

- Provides smooth, predictable blood pressure control<sup>1</sup>
- Offers instant access for rapid intervention<sup>2,3</sup>
- Enables practical point-of-use storage<sup>2</sup>
- Eliminates medication admixture errors

Ready-to-Use CARDENE I.V. is indicated for short-term management of hypertension when oral therapy is not feasible or desirable.<sup>1</sup>

**READY-TO-USE BAG**

**CARDENE® I.V.**  
*(nicardipine hydrochloride)*  
**PREMIXED INJECTION**



## Ready-to-Use CARDENE® I.V. SPECIFICATIONS

	40 mg in 200 mL (0.2 mg/mL)	20 mg in 200 mL (0.1 mg/mL)
<b>Drug Description</b>	<p>CARDENE I.V. Premixed Injection in either 0.83% Sodium Chloride or 5.0% Dextrose</p> <p>Galaxy® Ready-to-Use Bag with 40 mg in 200 mL (0.2 mg/mL)</p>	<p>CARDENE I.V. Premixed Injection in either 0.86% Sodium Chloride or 4.8% Dextrose</p> <p>Galaxy® Ready-to-Use Bag with 20 mg in 200 mL (0.1 mg/mL)</p>
<b>Stability/Storage</b>	<p>Manufacturer stability is 12 months. Protect from light, store in carton at controlled room temperature until ready to use. Refer to USP Controlled Room Temperature</p>	<p>Manufacturer stability is 12 months. Protect from light, store in carton at controlled room temperature until ready to use. Refer to USP Controlled Room Temperature</p>
<b>Dimensions</b>	<p>Box size: 9" H x 4.75" W x .875" D (contains 1 Ready-to-Use Bag)</p>	<p>Box size: 9" H x 4.75" W x .875" D (contains 1 Ready-to-Use Bag)</p>
<b>NDC Numbers</b>	<ul style="list-style-type: none"> <li>• Sodium Chloride: NDC # 24477-323-02 (1 pack of 10 boxes/bags)</li> <li>• Dextrose: NDC # 24477-324-02 (1 pack of 10 boxes/bags)</li> </ul>	<ul style="list-style-type: none"> <li>• Sodium Chloride: NDC # 24477-311-02 (1 pack of 10 boxes/bags)</li> <li>• Dextrose: NDC # 24477-312-02 (1 pack of 10 boxes/bags)</li> </ul>

## Ready-to-Use CARDENE® I.V. 40 mg in 200 mL (0.2 mg/mL)

### ORDERING INFORMATION

Wholesaler	Product	Wholesaler Order Numbers
<b>AmerisourceBergen</b>	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	006-577
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	008-946
<b>Cardinal Health</b>	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	4225173
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	4217923

<b>H. D. Smith</b>	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	221-0243
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	221-0250
<b>McKesson</b>	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	2538692
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	1437169
<b>Morris &amp; Dickson</b>	CARDENE I.V. Premixed Injection in 0.83% Sodium Chloride 40 mg in 200 mL (0.2 mg/mL)	977876
	CARDENE I.V. Premixed Injection in 5.0% Dextrose 40 mg in 200 mL (0.2 mg/mL)	946780

Please contact your GPO administrator for Ready-to-Use CARDENE I.V. contract pricing.

Supports compliance with The Joint Commission (TJC) standards and American Society of Health-System Pharmacists (ASHP) guidelines for dispensing and storing medications: When possible, medications shall be available in a ready-to-administer form.<sup>4,5</sup>

## ***Ready-to-Use CARDENE® I.V. 20 mg in 200 mL (0.1 mg/mL)***

### **ORDERING INFORMATION**

<b>Wholesaler</b>	<b>Product</b>	<b>Wholesaler Order Numbers</b>
<b>AmerisourceBergen</b>	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	777-060
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	830-455
<b>Cardinal Health</b>	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	4236352
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	4239638
<b>H. D. Smith</b>	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	218-0867
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	218-0875

<b>McKesson</b>	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	<b>1438753</b>
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	<b>1225234</b>
<b>Morris &amp; Dickson</b>	CARDENE I.V. Premixed Injection in 0.86% Sodium Chloride 20 mg in 200 mL (0.1 mg/mL)	<b>989632</b>
	CARDENE I.V. Premixed Injection in 4.8% Dextrose 20 mg in 200 mL (0.1 mg/mL)	<b>991596</b>

Please contact your GPO administrator for Ready-to-Use CARDENE I.V. contract pricing.

Supports compliance with TJC standards and ASHP guidelines for dispensing and storing medications:

When possible, medications shall be available in a ready-to-administer form.<sup>4,5</sup>

### Important Safety Information

Close monitoring of the blood pressure is required during therapy. CARDENE I.V. is contraindicated in patients with known hypersensitivity to the drug and in patients with advanced aortic stenosis. Reduction of diastolic pressure and reduced afterload may worsen rather than improve myocardial oxygen balance. Caution is advised when administering CARDENE I.V. to patients with impaired renal or hepatic function, in combination with a beta-blocker in patients with congestive heart failure, or portal hypertension. Observe caution in patients with significant left ventricular dysfunction due to possible negative inotropic effect. CARDENE I.V. gives no protection against the dangers of abrupt beta-blocker withdrawal; beta-blocker dosage should be gradually reduced. Levels of cyclosporine should be closely monitored during therapy. The most common side effects of CARDENE I.V. are headache (14.6%), hypotension (5.6%), nausea/vomiting (4.9%), and tachycardia (3.5%). Less frequent adverse effects, in each case occurring at 1.4%, include ECG abnormalities, postural hypotension, ventricular extrasystoles, injection-site reaction, dizziness, sweating and polyuria.

Please [click here](#) for full prescribing information.

For more information, visit [www.cardeneiv.com](http://www.cardeneiv.com) or e-mail us at [cardeneiv@ekrtx.com](mailto:cardeneiv@ekrtx.com).

For any additional questions, contact EKR Medical Information at 1-877-207-5802.

**References:** 1. CARDENE I.V. prescribing information, 2008. EKR Therapeutics, Bedminster, NJ. 2. Ruble J. Impact safety, efficiency, and the bottom line with premixed IV products. *Pharma Purchasing Prod.* February 2008:34-38, vi. 3. Fanikos J, Erickson A, Munz KE, et al. Observations on the use of ready-to-use and point-of-care activated parenteral products in automated dispensing cabinets in U.S. hospitals. *Am J Health-Syst Pharm.* 2007;64(19):2037-2043. 4. Rich DS. New JCAHO medication management standards for 2004. *Am J Health-Syst Pharm.* 2004;61(13):1349-1358. 5. American Society of Health-System Pharmacists. ASHP guidelines: minimum standard for pharmacies in hospitals. *Am J Health-Syst Pharm.* 1995;52(23):2711-2717.

CARDENE® is a registered trademark of EKR Therapeutics, Inc.

Galaxy® is a registered trademark of Baxter International.

